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Regulation of miR-483-3p by the O-linked
N-acetylglucosamine transferase links chemosensitivity
to glucose metabolism in liver cancer cells
F Pepe1,2, S Pagotto1,2, S Soliman1,2, C Rossi3, P Lanuti4, C Braconi5, R Mariani-Costantini1,2, R Visone1,2 and A Veronese1,2
The miR-483-3p is upregulated in several tumors, including liver tumors, where it inhibits TP53-dependent apoptosis by targeting the
pro-apoptotic gene BBC3/PUMA. The transcriptional regulation of the miR-483-3p could be driven by the β-catenin/USF1 complex,
independently from its host gene IGF2, and we previously demonstrated that in HepG2 hepatoblastoma cells carrying wild-type TP53
the upregulation of the miR-483-3p overcomes the antitumoral effects of the tumor-suppressor miR-145-5p by a mechanism involving
cellular glucose availability. Here we demonstrate that in HepG2 cells, the molecular link between glucose concentration and miR-483-
3p expression entails the O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT), which stabilizes the transcriptional complex
at the miR-483 promoter. HepG2 cells showed reduced miR-483-3p expression and increased susceptibility to 5-ﬂuorouracil
(5-FU)-induced apoptosis in presence of the inhibitor of glycolysis 2-deoxy-D-glucose (2-DG). However, in vivo experiments showed that
HepG2 cells with higher miR-483-3p expression were selected during tumor progression regardless of 5-FU treatment. Furthermore,
treatment with 2-DG alone did not signiﬁcantly reduce HepG2 xenograft load in immunodeﬁcient mice. In conclusion, we show that in
HepG2 cells glucose uptake increases the expression of the oncogenic miR-483-3p through the OGT pathway. This suggests that
depletion of the miR-483-3p may be a valuable therapeutic approach in liver cancer patients, but the use of inhibitors of glycolysis to
achieve this purpose could accelerate the selection of resistant neoplastic cell clones.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the ﬁfth most common form of
cancer worldwide and the third cause of cancer-related deaths.1,2
The current therapies are limited and often ineffective, thus there
is a need to identify new druggable molecular targets for the
development of novel therapeutics.
We have previously shown that miR-483-3p is overexpressed in
HCCs that carry mutations in β-catenin pathway genes3 and
in HCCs with wild-type TP53, as compared with those with
mutated TP53.4 The miR is transcribed through the β-catenin
(CTNNB1)/USF1 complex and targets the important downstream
apoptotic factor of TP53, PUMA.3,5 This gives to the miR a role in
HCC tumorigenesis, based on the induction of resistance to
apoptosis. Indeed, we have previously shown that in hepatoblas-
toma HepG2 cells, which carry mutated CTNNB1 and wild-type
TP53, constant activation of the TP53/miR-145-5p signaling selects
cells with high miR-483-3p expression that are resistant to
apoptosis. Depletion of miR-483-3p leads to apoptosis of these
cells. We also demonstrated that miR-145-5p inﬂuences the
expression of miR-483-3p in HepG2 cells with stimulatory or
inhibitory effects, depending on the availability of glucose in
the culture media.4 The involvement of glucose metabolism in the
regulation of miR-483-3p is supported by several studies that
connect CTNNB1 and USF1 activity to cellular glucose
metabolism,6–8 and by the fact that miR-483-3p maps at the
INS-IGF2 locus, which is involved in the insulin pathway.9,10
Here we show that in HepG2 cells the expression of miR-483-3p
is affected by the extracellular concentration of glucose. In fact
both glucose starvation and treatment with the glucose-mimic
2-DG reduce miR-483-3p expression. We identify as a key factor
of this regulation the O-linked β-N-acetylglucosamine transferase
(O-GlcNAc transferase, OGT). OGT is responsible for O-linked
β-N-Acetylglucosamine (O-GlcNAc) protein modiﬁcations using
the activated derivative of glucose metabolism Uridine dipho-
sphate N-acetylglucosamine or UDP-GlcNAc as substrate. There-
fore, protein O-GlcNAcylation is considered a cellular nutrient
sensor and a metabolic regulator.11,12
On the basis of our previous study, which showed increased cell
death susceptibility in HepG2 cells following depletion of the
miR-483-3p after inhibition of glucose metabolism, we tested 2-DG
as an adjuvant treatment, combined with 5-ﬂuorouracil (5-FU), on
a murine xenograft model with tumors induced by peritoneal
injection of HepG2 cells.
RESULTS
Glucose concentration affects miR-483-3p expression in HepG2 cell
line
MiR-483-3p is regulated by the transcriptional factors CTNNB1 and
USF1, therefore, on the basis of our previous observations, we
speculated that glucose deprivation could reduce the expression
of this miRNA. To study the effect of glucose deprivation on
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miR-483-3p expression, we cultured HepG2 cells with either
no-glucose or 10 mM glucose, and we collected cells at 10, 20,
36 and 48 h. We observed a gradual and signiﬁcant reduction of
miR-483-3p expression in cells cultured in no-glucose condition; on
the contrary, miR-483-3p expression increased over time in the
presence of glucose (Figure 1a).
To investigate if the CTNNB1/USF1 complex could have a direct
role on the increase of miR-483-3p expression in response to
glucose in HepG2 cells, we assayed the luciferase activity of a
vector carrying the E-Box-responsive element to CTNNB1/USF1
complex.3 The luciferase values showed reduced activity in
no-glucose relative to low glucose condition, indicating that the
glucose-dependent miR-483-3p regulation could be transcription-
ally controlled by CTNNB1/USFl (Figure 1b).
To strengthen these data, we treated HepG2 cells with the
glucose antagonist 2-deoxy-D-glucose (2-DG) for 48 h. We
observed a signiﬁcant reduction of the levels of both the
miR-483-3p and its precursor pri miR-483 in a 2-DG concentra-
tion-dependent way. The host gene IGF2 was not affected,
suggesting that glucose deprivation regulated the transcription
of miR-483-3p independently of IGF2 (Figure 1c).
To establish if 2-DG treatment affected miR-483-3p expression by
altering the activity of the CTNNB1/USF1 complex, we measured the
luciferase activity of the vectors carrying either wild-type or mutated
CTNNB1/USF1-responsive elements in HepG2 cells. Cells were
grown in low or high glucose media and treated or not with 2-
DG. The assay showed that, upon 2-DG treatment, the promoter
was less activated in both glucose conditions and the response to 2-
DG was absent or much less evident using the vector harboring the
mutant sequence (Figure 1d). Overall, these results indicate the
involvement of the CTNNB1/USF1/E-box complex in the regulation
of miR-483-3p expression.
To further investigate this hypothesis, we treated HepG2 cells
with 2-DG for 2 weeks and we observed a signiﬁcant reduction of
the levels of miR-483-3p and CTNNB1 (Figure 2a). Next, we
evaluated the activity of the CTNNB1/USF1 complex on the
miR-483 promoter in HepG2 cells upon 2-DG treatment. The
compound was able to reduce the interaction between the
CTNNB1/USF1 complex and the probe, as demonstrated by the
reduction of the speciﬁc bands ‘b’ (37%) and ‘c’ (–27%). The
speciﬁcity of the complex was demonstrated by the supershift
using the anti-USF1 antibody (band ‘a’) that showed a reduction of
intensity of about 38% after treatment (Figure 2b). We also noted
a reduction of the nuclear fraction of mutated CTNNB1 and USF1
in cells treated in the same conditions (Figure 2c). These ﬁndings
suggest the 2-DG inﬂuences miR-483-3p expression by reducing
both the amount of the CTNNB1/USF1 complex and its afﬁnity for
the E-box element upstream the miR-483 gene.
OGT activity regulates miR-483-3p expression acting at the
transcriptional level
OGT contributes to β-catenin stabilization13,14 and is related to the
insulin pathway;15 thus we investigated its role in the glucose-
dependent regulation of miR-483-3p. We evaluated miR-483-3p
Figure 1. Glucose deprivation and 2-DG treatment reduce miR-483-3p expression in HepG2 cell lines. (a) MiR-483-3p relative expression by
RT–qPCR in HepG2 cells cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) media without glucose (black bars) or with glucose
10 mM (gray bars) for 10, 20, 36 and 48 h. (b) Relative luciferase activity of the miR-483 promoter sequence containing the E-Box interacting
with CTNNB1/USF1 complex, in HepG2 cells cultured in DMEM media without glucose (black circles) or with glucose 10 mM (gray circles) for
0, 16 and 36 h. (c) MiR-483-3p, IGF2 (left y axis) and primiR-483 (right y axis) relative expression by RT–qPCR in HepG2 cells treated with 2-DG at
2 and 10 mM for 48 h. MiR-483-3p expression was normalized on U44, whereas IGF2 and primiR-483 on ACTB. (d) Relative luciferase activity of
the miR-483 promoter sequence containing the E-Box interacting with CTNNB1/USF1 complex, in HepG2 cells treated with 2-DG 5 mM in low
(black bars) or high (white bars) glucose condition (1 and 4.5 g/l, respectively) for 48 h. As control for the wild-type vector (wt) was used
mutated vector (mut) for the region interacting with the CTNNB1/USF1 complex. The graphs represent the means of technical triplicates with
the respective s.d. For statistical analysis, Student’s t-test was applied (*Po0.05; **Po0.01; ***Po0.001; ****Po0.0001).
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expression following either OGT depletion or 2-DG treatment in
HepG2 cells. Both OGT silencing by siRNA and 2-DG treatment led
to the suppression of miR-483-3p expression, with the greatest
effect achieved by the concomitant administration of 2-DG and
siRNA for OGT (siOGT) (Figure 3a).
To conﬁrm the regulation of miR-483-3p by OGT, we treated
HepG2 cells with azaserine, a OGT inhibitor. As shown in Figure 3b,
the compound reduced miR-483-3p and primiR-483-3p expression,
suggesting an effect on its transcription.
To study if OGT modulates miR-483-3p expression by acting on
the CTNNB1/USF1 complex, we conducted a chromatin immuno-
precipitation analysis for USF1 occupancy at the promoter of
miR-483 (6841F-7100R) in HepG2 cells transfected with either
siCTRL or siOGT. The 3′ UTR of the gene UBE3A (3UTR-UBE3A) was
added as control. The siOGT treatment reduced the afﬁnity
between USF1 and the miR-483 E-box sequence, suggesting that
OGT is fundamental for USF1 activity and in turn the regulation of
the miR-483-3p expression (Figure 3c). BUB1 antibody was used as
negative immunoprecipitation control, sonication and transfection
controls are reported in Supplementary Figure S1A.
To conﬁrm these data, we performed electrophoretic mobility
shift assay analysis of HepG2 nuclear protein extracts obtained
after transfection with OGT-siRNA or azaserine treatment; the
miR-483 E-box was used as probe. This showed that OGT inhibition
reduces the speciﬁc binding of the USF1 complex to the miR-483
E-box (Figure 3d, left). Western blot analysis of the nuclear protein
extract conﬁrmed OGT reduction after siOGT treatment. Despite
the physiologically increased expression of OGT protein after
azaserine treatment, a reduction of the overall glycosylation
status was observed by using the O-GlcNAc antibody (RL2), which
binds O-linked N-acetylglucosamine residues (Figure 3d, right).
The effects of azaserine and of OGT-siRNA on miR-483-3p and
primiR-483 are reported in Supplementary Figure S1B. Based on
our previously published evidence of an interplay between
miR-483-3p and the TP53 pathway,4 we measured the mRNA
expression of the TP53 transcriptional target BBC3 gene upon
silencing of OGT and 2-DG treatment. Decreased miR-483-3p
expression was concomitant to increased BBC3 RNA levels, index
of TP53 activity (Supplementary Figure S1C).
Then, given that the OGT gene is a predicted target of the
miR-483-3p by TargetScan (http://www.targetscan.org/vert_71/),
we tested by western blot OGT expression in HepG2 cells
transfected with either miR-483-3p mimic or anti-miR-483-3p
(AMO-483-3p). Compared with the controls, no differences in OGT
expression were observed (Supplementary Figure S1D), indicating
that OGT is not a target of miR-483-3p in HepG2 cells.
To verify whether CTNNB1 directly interacts with OGT in our cell
model, we performed an immunoprecipitation analysis in HepG2
cells transfected with a vector carrying USF1. We observed an
interaction between CTNNB1 and OGT, suggesting that OGT
regulated miR-483-3p expression by affecting the stability of
CTNNB1 (Supplementary Figure S2).
Effect of 2-DG on HepG2 cells in vitro and in vivo
Given that miR-483-3p was proven to have an oncogenic role
in HCC5 and to inhibit the pro-apoptotic pathway induced by
miR-145-5p and TP53,4 we hypothesize that 2-DG could
reduce miR-483-3p expression and increase the efﬁcacy of
chemotherapeutic treatments in HCC cells.
Anti-miR-483-3p in combination with 2-DG was tested on
HepG2 cells treated with different anticancer drugs, including
sorafenib, doxorubicin and 5-FU. Inhibition of miR-483-3p
signiﬁcantly increased 5-FU-induced apoptosis in 2-DG treated
cells (Supplementary Figure S3A). Next, we treated HepG2 cells
with 2-DG (10 and 20 mM) alone or in combination with 5-FU
(2.5 μM) and we evaluated caspase 3/7 activity. The combination of
the two compounds resulted in higher caspase activity compared
with the control (Figure 4a), which was conﬁrmed by analysis of
Figure 2. 2-DG treatment affects miR-483-3p expression at transcriptional level. (a) miR-483-3p relative expression by RT–qPCR (left panel), and
CTNNB1 (wild-type and mutated) protein relative expression by western blot (right panel), in HepG2 cells treated with 2-DG 20 mM for 2 weeks
in high glucose. The graphs represent the means of technical triplicates with the respective s.d. For statistical analysis, Student’s t-test
was applied (**Po0.01). The right panel shows the percentage variation with respect to the relative control by densitometry analysis. (b)
Electrophoretic mobility shift assay (EMSA) of nuclear extract (NE) from HepG2 cells treated with 2-DG 5 mM using the miR-483 E-box probe.
The speciﬁc complexes are indicated with black arrows (b, c). Arrow a shows the supershift generated by USF1 complex. Densitometry analysis
is shown. EMSA was performed once. (c) Protein relative expression of cytoplasmic (CE) and nuclear (NE) CTNNB1 and USF1 by western blot.
Densitometry analysis is shown.
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annexin V (Figure 4b). Reduction of the miR-483-3p expression is
documented in Supplementary Figure S3B.
To evaluate the effect of the drugs in vivo, we generated a
xenograft model in which NOD scid gamma mice were
intraperitoneally inoculated with HepG2. Mice were treated with
intraperitoneal injection of 2-DG (250 mg/kg one injection), or
5-FU (12.5 mg/kg for 3 consecutive days), or combination of the
two drugs, or phosphate-buffered saline (PBS). We alternated a
week of treatment with a week of rest, for a total of three cycles
(Figure 5a). After 3 days from the last treatment, the mice were
sacriﬁced and the xenografts were weighted. We observed
reduction of tumor volume after treatment with 5-FU; however,
addition of 2-DG did not improve 5-FU efﬁcacy (Figure 5b). To
explain this phenomenon, we analyzed miR-483-3p RNA expres-
sion together with the protein levels of PUMA and CTNNB1, which
are targets of the miR. Compared with HepG2 cells, in almost all
xenografts miR-483-3p showed signiﬁcantly increased expression,
concomitant with downregulation of its targets (Figure 5c)
suggesting that the 2-DG, at the evaluated concentration and
mode of administration, did not affect the expression of the miR
in vivo.
DISCUSSION
In liver cancer, the expression of the miR-483-3p is related to the
mutational status of TP53 and CTNNB1 genes and to impaired
epigenetic mechanisms affecting the IGF2/miR-483/H19 locus. The
overexpression of of the miR-483-3p directly inhibits protein
expression of the pro-apoptotic factor TP53 upregulated mod-
ulator of apoptosis (PUMA).3–5
Here we demonstrate that cellular glucose availability
is involved in the modulation of miR-483-3p and identiﬁed
OGT activity as a molecular link between glucose and
miR-483-3p expression. OGT mediates the addition of a
N-acetylglucosamine in O-glycosidic linkage (O-GlcNAcylation) to
serine or threonine residues16,17 and inﬂuences several cellular
processes, such as epigenetic control of RNA transcription,18
insulin signaling,15 Wnt/β-catenin signaling13,14 and mouse
embryonic development.19 Inhibition of OGT activity results in
decreased miR-483-3p expression, concurrently with weakened
afﬁnity of the transcriptional complex CTNNB1/USF1 to the
responsive sequence upstream the miR-483 gene. Although our
data show that OGT inﬂuences the CTNNB1/USF1 complex acting
at the responsive E-box element, we cannot exclude involvement
of other molecular mechanisms. Indeed OGT is implicated in
RNA transcription by O-GlcNAcylation of RNA polymerase II20
and of several transcription factors, such as SP121 and MYC,22
in addition to CTNNB1.13,14
The reprogramming of glucose metabolism and its epigenetics
aspects are relevant to the development of new approaches
to cancer treatment.23–25 In this regard, the antitumoral effects
of 2-DG are under intense study,26,27 and we found that
2-DG treatment inhibits miR-483-3p expression in HepG2 cells,
probably by reducing the OGT substrate, and equally enhances
the apoptotic rate of HepG2 cells treated with 5-FU. We decided to
investigate the effects of co-treatment with 2-DG and 5-FU on
Figure 3. OGT activity regulates miR-483-3p expression. (a) MiR-483-3p relative expression by RT–qPCR of HepG2 cells transfected with siRNA for
OGT and treated with 2-DG 5 mM for 48 h (lower panel). The lower panel shows the effective OGT protein reduction by siRNA treatment by
western blot analysis (b). PrimiR-483 (left y axis) andmiR-483-3p (right y axis) relative expression by RT–qPCR, of HepG2 cells treated with azaserine
100 μM for 24 h. (c) Chromatin immunoprecipitation (ChIP) analysis for USF1 occupancy at the promoter of the miR-483 (6841F-7100R) and at the
3′ UTR of UBE3A (3UTR-UBE3A) as control, by RT–qPCR (normalized on input DNA) in OGT-depleted HepG2 cells for 19 h. The BUB1 antibody was
used as negative control. (d) (Left) Electrophoretic mobility shift assay (EMSA) analysis of nuclear extract (NE) from HepG2 cells transfected with
siRNA for OGT or treated with azaserine 200 μM for 24 h using the miR-483 E-box probe. The speciﬁc complexes are indicated with black arrows
(b, c). EMSA for lanes siCTRL and siOGT was performed once. (Right) OGT, β-catenin, USF1 protein relative expression and glycosylation status
(using RL2 antibody) of the nuclear extract by western blot from HepG2 cells transfected with siRNA for OGT or treated with azaserine 200 μM for
24 h. Densitometry analysis is shown. For statistical analysis, Student’s t-test was applied (**Po0.01; ***Po0.001).
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HepG2 xenografts in vivo. By analyzing the engrafted tumor
masses, we found that tumor load decreased less in the group
of mice co-treated with 2-DG and 5-FU compared with the
group treated with 5-FU alone. This could be explained by the fact
that miR-483-3p was not affected by 2-DG at the dose
and modality of administration used. Instead of the predicted
reduction of miR-483-3p expression, the xenografts showed
induction of the miRNA after 2-DG and 5-FU co-treatment. This
could be due to a cellular selection of clones with higher
expression of the miRNA, an event that we previously observed
also studying TP53 activation.4
Altogether these results prove that the glucose/OGT/miR-483-3p
signaling axis has an important role in the anti-apoptotic
mechanisms of liver cancer and can be an important dowel to
understand the oncogenic mechanisms that link metabolism
to resistance to drugs and apoptosis. Therefore, miR-483-3p may
be a promising target in the management of liver cancer patients,
but the modality of its modulation should not include 2-DG or
other drugs that cause general metabolic inhibition, an effect that
could be counterproductive, as it would increase the selective
pressure for the most adaptive cancer cells.
MATERIALS AND METHODS
Cell lines, drugs treatment and transfection
HepG2 cell line, from American Type Culture Collection (ATCC, Manassas, VA,
USA), were cultured with Dulbecco’s modiﬁed Eagle’s medium, with low or
high glucose concentration (1 g and 4.5 g per liter, respectively), completed
with 10% fetal bovine serum European approved, L-glutamine, penicillin,
streptomycin and Normocin (100 ug/ml) (InvivoGen, San Diego, CA, USA).
The 2-DG (D6134), 5-FU (F6627) and azaserine (A4142) were obtained from
Sigma Aldrich (St Louis, MO, USA).MiR-483-3p precursor and negative control
2 ribo-oligonucleotide (NC2) were from Ambion (Thermo Fisher Scientiﬁc,
Waltham, MA, USA). Anti-miRNA oligonucleotides (AMO) against miR-483-3p
and against the GFP gene (AMO negative control) were from Fidelity System
(Gaithersburg, MD, USA). RNA interfering for OGT (sc-40780) and scramble
control (sc-37007) were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Transfection of miRNAs, AMOs and expression vectors was carried out
with Lipofectamine 2000 (Thermo Fisher Scientiﬁc, Walmar, MA, USA) in
accordance with the procedures of the manufacturer.
RNA extraction, cDNA and quantitative real-time PCR (RT–qPCR)
for miRNA and mRNA
Puriﬁcation of total RNA using Qiazol reagent (Qiagen, Hilden, Germany) was
carried out following the manufacturer’s instructions. To avoid genomic
contamination in the quantiﬁcation of pre-mRNA and pri-miRNA, RNA
samples used for the analysis were previously treated with DNase (TURBO
DNA-free Kit; Thermo Fisher Scientiﬁc). To analyze the mature miRNA
expression normalized on RNU44, we synthesized speciﬁc miRNA comple-
mentary DNA (cDNA) from RNA samples. In all, 25 ng of total RNA were
reverse transcribed using the cDNA Reverse Transcription Kit (Thermo Fisher
Scientiﬁc) and the speciﬁc stem loop RT primers designed with a
modiﬁcation to include the UPL #21 complementary sequence.28,29 The
mix for the reverse transcription reaction included: 5 μl of RNA (5 ng/μl); 2 μl
of 10X reverse transcription buffer; 0.2 μl of 100 mM dNTPs; 0.2 μl of RNase
inhibitor (20 U/μl); 1 μl of MultiScribe reverse transcriptase (50 U/μl); 0.5 μl of
speciﬁc loop primers (1 μM) (diluted in TRIS/HCl 2.5 mM pH 8.5) for miRNA and
RNU44; and nuclease-free water to reach the ﬁnal volume of 20 μl. The
pulsed RT reaction was carried out in 0.2 ml tubes at 16 °C for 30 min,
followed by 60 cycles (30 °C for 30 s, 42 °C for 30 s, 50 °C for 1 s) with the ﬁnal
step of 85 °C for 5 min, using a thermal cycler GeneAmp PCR System 9700
(Thermo Fisher Scientiﬁc). Then qPCRs were performed. In total, 10 μl of qPCR
reaction included: 3.4 μl of RNase-free water; 5 μl of Mastermix 2X (FastStart
Universal Probe Mastermix, Roche, Basilea, Svizzera); 0.5 μl of speciﬁc miRNA
primer forward (20 μM); 0.5 μl of universal reverse primer (20 μM); 0,1 μl of
Universal Probe Library 21 (4686942001, Roche); 1 μl of cDNA diluted.
To quantify mRNAs normalized on ACTB expression, cDNA
was generated using the High Capacity cDNA reverse transcription kit
Figure 4. Effect of 2-DG and 5-FU combination in vitro. (a) Caspase 3/7 activation, normalized on ACTB protein expression measured by
western blot (data not shown), and (b) Annexin V analysis of HepG2 cells treated with 2-DG (10 and 20 mM), 5-FU (2.5 μM) or in combination in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) low glucose for 24 h. Only bright annexin was measured as high apoptosis rate was detectable
in treated cells.
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(Thermo Fisher Scientiﬁc). The 20 μl of reverse transcription reaction
included: 8.2 μl nuclease-free water; 2 μl of 10X reverse transcription
buffer; 0.8 μl of 100 mM dNTPs; 1 μl of RNase inhibitor (20 U/μl); 1μl of
MultiScribe reverse; 2 μl of random primers; 1 μl transcriptase (50 U/μl);
and 5 μl of RNA (100 ng/μl). The reactions were carried out in 0.2 ml tubes
at 25 °C for 10 min, 37 °C for 2 h and 85 °C for 5 min, using the thermal
cycler GeneAmp PCR System 9700 (Thermo Fisher Scientiﬁc). The cDNA
obtained was diluted 1:2 and used for the qPCR using the kit FastStart
Universal Probe Mastermix. The 10 μl of reaction included: 2.4 μl of
RNase-free water, 5 μl of Mastermix 2X, 0.5 μl of speciﬁc mRNA primer
forward (20 μM), 0.5 μl of speciﬁc mRNA primer reverse; 0.1 μl of speciﬁc
probe (Universal probe library system, Roche) and 2 μl of cDNA
diluted. Primer sequences and relative ﬂuorescent 6-Carboxyﬂuorescein
probes were obtained by the ‘Universal Probe Library Assay Design Center’
online software (https://lifescience.roche.com). When the identiﬁcation of
a suitable UPL probe was not possible, SYBR green technologies were used
for the quantiﬁcation of a speciﬁc sequence (QuantiFast SYBR Green PCR
Kit; Qiagen), in this case the 10 μl of reaction included: 2.8 μl of RNase-free
water, 5 μl of SYBR green Mastermix 2X (Qiagen); 0.1 μl of speciﬁc forward
and reverse primer (20 μM); and 2 μl of cDNA diluted (1:2).
qPCR reactions were conducted using an ABI PRISM 7900HT Sequence
Detection System (Thermo Fisher Scientiﬁc) or the CFX96 Touch Real-Time
PCR Detection System (Bio-Rad, Hercules, CA, USA). All samples were run in
triplicate, and the levels of miRNA and mRNA were measured using the
threshold cycle (Ct). The amount of target, normalized to an endogenous
reference (RNU44 for miRNA and ACTB for mRNA), is given by 2−ΔCt, with
formula 2–(Ct sample–(mean triplicate of the Ct reference)) in base to the
comparative Ct method (Applied Biosystems User Bulletin no. 2).
Primer sequences used are provided in Supplementary Table 1.
Protein extraction, quantiﬁcation and western blot
Total protein extraction were performed by using M-PER Mammalian
Protein Extraction Reagent (Thermo Fisher Scientiﬁc) freshly supplemented
with protease and phosphatase inhibitors (Thermo Scientiﬁc); whereas the
NePer kit (Thermo Fisher Scientiﬁc) was used for nuclear and cytoplasmic
extraction following the manufacturer’s instructions. Protein concentration
was evaluated by spectrophotometric analysis using the Bio-Rad Protein
Assay Dye Reagent (Bio-Rad) and the GeneQuant pro spectrophotometer
(Biochrom Ltd., Cambrige, UK). Up to 50 μg of protein were loaded onto
gel Criterion TGX Stain Free Gel, 4–20% (Bio-Rad) and run at 80 V for 2 h.
Proteins were transferred in polyvinylidene diﬂuoride membrane at 20 V
overnight. Blots were blocked with non-fat dry milk 5% (Cell Signaling
Technology, Danvers, MA, USA) for 1 h at room temperature and incubated
Figure 5. Effect of 2-DG and 5-FU combination in vivo. (a) Time table of the in vivo experiment. Sixteen NSG mice were randomly divided in
four groups of treatment: vehicle (PBS), 2-DG, 5-FU and 2-DG+5-FU. Weeks and days of the different treatments are reported. At day 1, the
mice were injected with 10 × 106 HepG2 cells. At the second, fourth and sixth week, the mice were treated with 2-DG, 5-FU, both the drugs or
the vehicle. Every day of treatment, the mice received a single intraperitoneal injection of 200 μl. Every drug or combination was dissolved
in PBS. In (b), the total weight of xenografts obtained by NOD scid gamma (NSG) mice is reported. (c) miR-483-3p relative expression,
normalized on RNU44, by RT–qPCR from the same samples (white bars) and from HepG2 cells before inoculation in mice (black bar). The
graphs represents the means of technical triplicates with the respective s.d. For statistical analysis, Student’s t-test was applied (*Po0.05;
**Po0.01). (d) Protein relative expression by western blot of CTNNB1 and PUMA in tumors induced in xenografts model. Densitometry
analysis is shown. Every value is normalized on relative ACTB, and it reports the percentage of difference for every group of treatment vs the
control group.
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with speciﬁc primary antibody from 2 h to overnight at 4 °C. After Tris-
buffered saline-Tween washes, blots were incubated with peroxidase-
conjugated anti-mouse or anti-rabbit antibodies for 1 h at room
temperature. Detection was conducted by chemiluminescent assay (Pierce
ECL western blotting substrate, Thermo Fisher Scientiﬁc). To quantify
western blot signals, digital images of autoradiographs were acquired, and
band signals were quantiﬁed in the linear range of the scanner using the
software ImageJ (http://imagej.net/Welcome). Protein loading were
evaluated by measuring the β-actin or vinculin protein expression. The
list of the antibodies used is provided in Supplementary Table 2.
Luciferase assay
HepG2 cells were seeded in a 96-well plate and transfected with the
DNA vectors pRLTK (Promega, Madison, WI, USA), which expresses the
reference renilla luciferase, and the PGL4 Luciferase Reporter Vector,
(Promega) containing the E-Box sequence interacting with the CTNNB1/
USF1 complex (pGL4 6839-6910), expressing the luciferase. The DNA vectors
were transfected by Lipofectamine (Thermo Fisher Scientiﬁc) following the
manufacturer’s procedure. After 48 h, the luminescence was evaluated with
the Dual-Glo Luciferase Assay System (Promega) using a Lumat LB 9507 the
luminometer (Berthold Technologies, Bad Wildbad, Germany).
Electrophoretic mobility shift assay
Protein/DNA binding was determined by electrophoretic mobility shift assay
according to the manufacturer’s procedure (LightShift Chemiluminescent
EMSA Kit; Pierce, Thermo Fisher Scientiﬁc) with biotinylated probes
(Fidelity System, Gaithersburg, MD, USA; Supplementary Table 1). Nuclear
protein extract (NE) from HepG2 were incubated withmiR-483 E-box wild-type
biotinylated probe (OligoBio) with or without 100× E-box unlabeled probe,
and/or with speciﬁc polyclonal USF1 antibody. The DNA–protein complexes
were resolved on 5% nondenaturing acrylamide gels and visualized by
chemoluminescent assay and exposure to autoradiographic ﬁlms.
Immunoprecipitations (chromatin immunoprecipitation)
Immunoprecipitation was executed using the kit Magna ChIP Protein
A+G Magnetic Beads (Merck Millipore, Billerica, MA, USA) following the
manufacturer’s instructions. Cells were ﬁxed with formaldehyde (1% 10 min
at room temperature), glycine was added to stop the reaction and after
5 min, then washed with ice-cold cold PBS to remove completely the
formaldehyde. Cells were collected by scraping in PBS ice cold containing 1x
proteinase inhibitor, pelleted and lysed with buffer containing proteinase
inhibitors. After vortex and centrifugation, the supernatant was separated
and the nuclear lysis buffer added to the pellet. After centrifugation to
remove the debris, the protein nuclear extract was sonicated using an IKA
Labor technik U200 S Control apparatus (IKA-Works, Staufen im Breisgau,
Germany, 30% amplitude, 0.3-s pulse rate or 30% cycle duty for 1 min). Part
of the lysate sonicated was denatured and run for gel electrophoresis to
conﬁrm that the length of the DNA fragments was between the 200 and
1000 base pairs. The rest of the lysate was centrifuged to remove debris and
used for the different immunoprecipitations. Each immunoprecipitation was
conducted with 50 μl of lysate diluted in 450 μl of dilution buffer containing
protease inhibitors. In all, 5 μl were removed and keep at − 80 °C (input). For
each experimental condition, 1 µg of USF1 antibody or controls (mouse IgG,
BUB1 antibody) and 20 µl of fully resuspended protein A/G magnetics
beads were added to the diluted lysate. All the reactions were incubated
overnight at 4 °C with rotation. The protein A/G magnetic beads were pellet
with the magnetic separator and washed with speciﬁc salt solutions. Then
elution buffer containing the proteinase K was added and the samples were
incubated at 62 °C for 2 h and 95 °C for 10 min with shaking. Beads were
separated with the magnetic separator and the supernatant containing the
DNA associated at the protein complexes were puriﬁed by columns. In all,
2 μl of the obtained DNA were used for qPCR to quantify the miR-483-3p
promoter region using the primers 6841_F and 7100_R, or the 3’UTR region
of UBE3A as control. For qPCRs, every sample was analyzed in triplicate.
Caspase 3/7 activity and Annexin V ﬂow cytometric analysis
HepG2 and Hep3B cells were seeded in a 96-well plate with opaque
borders. After the transfection and/or the drug treatment, the cellular
apoptosis was evaluated by the Caspase-Glo 3/7 Assay (Promega),
following the manufacturer’s procedure. The luminescence was evaluated
by the Veritas Microplate Luminometer (Turner BioSystems, Promega).
Every sample was analyzed in triplicate.
Another assay to measure apoptosis was performed by ﬂuorescence-
activated cell sorter using Annexin V-APC conjugated detection kit
(Enzo Life Sciences, Farmingdale, NY, USA). After washing in PBS, cells
were stained using Annexin V antibody in speciﬁc binding buffer for
10 min in darkness, according with the manufacturer’s procedure. Then
cellular apoptosis was analyzed by ﬂow cytometer (FACSCalibur, BD).
Mice treatment and management
Animal studies were approved by institutional and government ethical
committees (823/2015-PR). Sixteen NOD scid gamma (Charles River
Breeding Laboratories, Wilmington, MA, USA) male mice were used (four
for each group). No mice randomization was performed and no blinding
procedures were performed. All mice were housed in the Aging Research
Center (CeSI-MeT, Chieti, Italy) animal facility. They were maintained on a
12-h light/dark cycle with ad libitum access to water and normal chow. The
suffering of the mice was evaluated using the ‘mouse grimace scale'30 by
the responsible of the stabulary and no suffering status was registered
during the management and the treatment. The cages, the water, the
chow and every items or substance that was in contact with the mice were
sterile. The mice of 6 weeks were inoculated with 107 HepG2 cells by
intraperitoneal injection using a 26-gauge syringe and divided in four
groups of treatment: PBS, 2-DG, 5-FU and 2-DG+5-FU.
Then, three cycles of treatment were executed at 11, 25 and 39 day from
the HepG2 injection. The administration of 2-DG (250 mg/kg) was once at
treatment, whereas for 5-FU was decided to execute three separate
administration during the week of treatment (12.5 mg/kg each). Each drug
was dissolved in sterile PBS, and administered by intraperitoneal injection
at a ﬁnal volume of 200 μl for mouse. We used the no toxic dose of 2-DG31
alone or in combination with 5-FU to treat mice. At 45 days from the
injection of the cells, mice were sacriﬁced by CO2 chamber. Tumor masses
were photographed, weighted and putted in liquid nitrogen until RNA and
protein extraction.
Statistical analysis
All the in vitro experiments were replicated either twice or in similar
conditions or in different cellular models unless not speciﬁed in the
legends. The variation within each group has been evaluated as s.d. and for
the in vivo results, the Levene's test was not signiﬁcant to indicate the
homoscedasticity of the data. Signiﬁcance was determined with the
two-tailed Student’s t-test. A P-value threshold o0.05 was considered
signiﬁcant (marked as *), P valueo0.01, o0.001 and o0.0001 are marked
as **, *** and ****, respectively. In graphs, values were presented as the
mean± s.d.
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